No new digest content identified.
National Health Commission of the People’s Republic of China
Sept 5: Daily briefing on novel coronavirus cases in China
On Sept 4, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 10 new cases of confirmed infections.
Four Chinese COVID-19 vaccines undergoing phase-3 clinical trials
BEIJING — Four Chinese COVID-19 vaccine candidates have started international phase-3 clinical trials, according to the State Council joint prevention and control mechanism against COVID-19.
Some of the phase-3 trials are expected to complete the first round of vaccinations in early September, with preliminary data expected as early as November.
Phase-3 clinical trials usually involve thousands of people to verify the safety and effectiveness of the vaccines, which are key to their market approval.
As the epidemic has been brought under control in China, the country no longer has conditions for large-scale clinical trials, so all the phase-3 trials are being carried out overseas.
Two inactivated COVID-19 vaccines developed by the China National Biotec Group (CNBG) have been approved for phase-3 clinical trials in several countries in the Middle East and South America, involving more than 30,000 people, according to Yang Xiaoming, president of the CNBG…